Dr. Reddy’s Laboratories has launched its generic Semaglutide Injection in Canada, marking a significant milestone as the first company to receive Health Canada approval for this medication. Canada becomes the first G7 country to authorize the generic version, which is indicated for the once-weekly treatment of adults with type 2 diabetes. This expansion strengthens the company’s commitment to providing affordable, high-quality GLP-1 therapies in global markets following their recent launch in India.
Strategic Market Expansion
Dr. Reddy’s Laboratories has officially introduced its generic Semaglutide Injection to the Canadian pharmaceutical market. The launch follows the receipt of the Notice of Compliance (NOC) from Health Canada on April 28, 2026. This development underscores the company’s global expertise in complex drug and peptide development and its ability to rapidly move from regulatory approval to market availability.
Product Specifications and Indications
The generic injection is designed as a once-weekly treatment for adults diagnosed with type 2 diabetes mellitus. It serves to improve glycemic control when used alongside a regimen of diet and exercise. The product is supplied as a sterile solution in a pre-filled pen format, offered in two specific strengths:
- 2 mg/pen: Designed to deliver 0.25 mg or 0.5 mg doses.
- 4 mg/pen: Designed to deliver 1 mg doses.
Focus on Global Diabetes Care
This launch represents a pivotal advancement in the company’s efforts to increase patient access to GLP-1 therapies. Erez Israeli, Chief Executive Officer, noted that this move aligns with the company’s broader objective of expanding its reach across global markets. The Canadian rollout leverages the momentum established by the recent introduction of the drug in India under the brand name Obeda®. Dr. Reddy’s continues to prioritize the diabetes and endocrinology sector as a key pillar of its long-term growth strategy.
Source: BSE
